Suppr超能文献

遗传性癌症风险评估中多基因评分的临床应用考量:接受者对影响因素及策略的看法

Considering Clinical Implementation of Polygenic Scores in Hereditary Cancer Risk Assessment: Recipients' Perspectives on Influencing Factors and Strategies.

作者信息

Purvis Rebecca, Taylor Natalie, James Paul, Young Mary-Anne, Forrest Laura E

机构信息

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, 3000, Australia.

Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia.

出版信息

Patient. 2025 Jun 28. doi: 10.1007/s40271-025-00747-5.

Abstract

BACKGROUND

Polygenic scores (PGS) capture a proportion of the genomic liability for cancer in unselected and high-risk cohorts, with meaningful application in improving risk-stratified screening and management. However, there are significant evidence gaps regarding future clinical implementation. Despite being key interest-holders, recipient views are underrepresented. The objective of this study was to explore recipients' views on the clinical implementation of PGS for hereditary cancer risk assessment in Australian cancer genetics clinics.

METHODS

Three video-conferenced focus groups were conducted with recipients who had been given their breast and ovarian cancer PGS through the PRiMo trial. Nominal Group Technique was used to enable evaluation of implementation determinants and strategies, and priority setting. Descriptive and deductive content analyses were conducted utilising the Consolidated Framework for Implementation Research and the Expert Recommendations for Implementing Change compilation of facilitative strategies.

RESULTS

Participants (N = 10) were female, with an average age of 36 years (range 18-70 years). Of these, 50% (N = 5) experienced a change in their hereditary cancer risk assessment due to their PGS. Participants prioritised the positive value and impact of PGS, and the behavioural characteristics of recipients, notably their knowledge and expectations of PGS and cancer genetics clinics, as major determinants of implementation success. Implementation strategies that prepared and supported recipients to access, engage, and use PGS were emphasised, with a focus on a clear results report, educational resources, in-clinic resources, and delivery of ongoing good clinical follow-up.

CONCLUSION

Evidence-based strategies should be deployed to address recipients' priority barriers to the clinical implementation of PGS for hereditary cancer risk assessment. Centralising recipient voices in implementation design will improve effectiveness and success.

摘要

背景

多基因评分(PGS)在未选择的和高危队列中捕捉了一部分癌症的基因组易感性,在改善风险分层筛查和管理方面有重要应用。然而,关于未来临床应用存在重大证据空白。尽管接受者是关键利益相关者,但他们的观点在相关研究中未得到充分体现。本研究的目的是探讨澳大利亚癌症遗传学诊所中接受者对将PGS用于遗传性癌症风险评估的临床应用的看法。

方法

对通过PRiMo试验获得乳腺癌和卵巢癌PGS的接受者进行了三次视频会议焦点小组讨论。采用名义小组技术来评估实施的决定因素和策略以及确定优先事项。利用实施研究综合框架和实施变革促进策略专家建议汇编进行描述性和演绎性内容分析。

结果

参与者(N = 10)均为女性,平均年龄36岁(范围18 - 70岁)。其中,50%(N = 5)因PGS导致其遗传性癌症风险评估发生了变化。参与者将PGS的积极价值和影响以及接受者的行为特征(尤其是他们对PGS和癌症遗传学诊所的了解及期望)视为实施成功的主要决定因素。强调了为接受者准备和支持其获取、参与和使用PGS的实施策略,重点是清晰的结果报告、教育资源、诊所内资源以及持续提供良好的临床随访服务。

结论

应部署基于证据的策略来解决接受者在将PGS用于遗传性癌症风险评估的临床应用方面的优先障碍。在实施设计中纳入接受者的意见将提高有效性和成功率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验